

## 5th Meeting of the Global Task Force for Cholera Control (GTFCC) Working Group on Oral Cholera Vaccine AGENDA

## **Objectives:**

The OCV WG meeting will be an opportunity to get an update on the implementation of the *Ending Cholera Roadmap* in countries. More specifically the proposed objectives and topics for discussion are as follows:

• To provide an update on the implementation of the *Ending Cholera Roadmap* and integration of OCV in cholera control plans including:

- Perspectives from participating countries
- Lessons learnt and way forward to engage countries in cholera control
- To discuss perspectives on OCV use moving forward including:
  - Outcomes of the Gavi Vaccine Investment Strategy and long-term support for OCV
  - Update on supply availability for 2019 and beyond

 $\circ$  GTFCC support to countries and OCV use – follow up from the 2018 GTFCC annual

- meeting and discussions on the process to access OCV
  - Standard approach for M&E
- To review and validate the OCV research agenda:
  - Feedback from the GTFCC research agenda meeting and cholera research priorities –
  - updates from other GTFCC WGs
    - Update from partners on research projects
    - Validation of the OCV WG research priorities

Dates: 5 and 6 December 2018

Location: Veyrier du Lac, France

Venue: Les Pensières Conférence Centre, 55 Route d'Annecy, 74290 Veyrier-du-Lac, France

Session	Topics
	WEDNESDAY 5 DECEMBER
8.30-9.00	Welcome coffee
9.00-9.30	INTRODUCTION
	Opening Remarks – Kashmira Date, Chair of the OCV WG
	Introduction of participants and meeting objectives
9.30-10.30	GTFCC UPDATE
	Update on the implementation of the Ending Cholera Roadmap and countries engagement – Dominique Legros, GTFCC Secretariat
	Overview of OCV use in the last year and perspectives going forward – Lorenzo Pezzoli, GTFCC Secretariat
	Group discussion
10.30-10.50	Coffee Break
10.50-13.00	PRESENTATION FROM COUNTRIES on OCV USE AND PERSPECTIVE FOR USE CHOLERA CONTROL EFFORTS (part 1)
	Haiti - Katilla Pierre, Ministry of Public Health and Population
	Malawi – Wiseman Chimwaza, Ministry of Health, Malawi
	Nigeria - Dorothy Nwodo, National Primary Healthcare Development Agency
	Zimbabwe - Marc Poncin, WHO consultant
	Group discussion
13.00 -14.00	Lunch Break
14.00-14.45	PRESENTATION FROM COUNTRIES – USE OF OCV IN PROTRACTED CRISIS
	<ul> <li>South Sudan – Joseph Wamala, WHO Country Office</li> </ul>
	Yemen - Jean Luc Poncelet, WHO Country Office
	Group discussion
14.45 -15.30	NEXT STEPS ON THE OCV STOCKPILE AND SUPPLY AVAILABILITY
	Update from Gavi Vaccine Investment Strategy– <i>Adam Soble, Gavi</i>
	OCV supply availability overview – Guillermo Gimeno, UNICEF SD
	Feedback from the ICG Meeting – Eduardo Vargas, ICG Secretariat
	Group discussion
15.30-15.45	Coffee break
15.45 -17.30	IMPLEMENTING THE ROADMAP - PERSPECTIVES ON FUTURE ACCESS TO OCV – part 1
	Implementation of the Ending Cholera Roadmap: Integrating OCV in National Cholera Plans – Lorenzo Pezzoli, GTFCC Secretariat
	Designing Gavi cholera programme – key principles – Adam Soble, Gavi
	Introduction to group work—Johanna Fihman, GTFCC Secretariat

	BREAK INTO 2 GROUPS:
	Group 1: Recommendations on application requirements and criteria for review of OCV requests
	<ul> <li>Group 2: Risks and mitigation measures to ensure strategic and effective use of OCV</li> </ul>
	DRINKS FROM 18.00 FOLLOWED BY DINER AT FONDATION MERIEUX
	THURSDAY 6 DECEMBER
9.00 - 10.00	IMPLEMENTING THE ROADMAP – GTFCC SUPPORT TO COUNTRIES
	Update on the GTFCC Framework to support countries in the development of Cholera Plans – <i>Melissa Ko, MMGH</i>
	GTFCC Working Groups update
	Surveillance Epidemiology WG- <i>Francisco Nogareda</i>
	Surveillance Laboratory and Case Management WGs – David Olson
	WASH WG – Monica Ramos, UNICEF
	Group discussion
10.00-11.00	IMPLEMENTING THE ROADMAP - PERSPECTIVES ON FUTURE ACCESS TO OCV – part 2
	Feedback from group work in plenary - Rapporteurs
	Group discussion: review and agreement on recommendations on process to access OCV as part of cholera national plans in line with the framework tool
11.00-11.15	Coffee Break
11.15 -12.00	UDPATE PARTICIPATING MANUFACTURERS
	Update from participating manufacturers:
	Sanofi - Catherine Bravo
	EuBiologics - Rachel Park
	Hilleman Lab - Sourabh Sobti
	Group discussion
12.00-13.00	PARTNERS UPDATE – part 1
	Updates from:
	MSF, Iza Ciglenecki
	DOVE, David Sack
	• JHU, Andrew Azman
12.00.14.00	IRC, Michelle Gayer
13.00 -14.00	Lunch Break
14.00-15.15	PARTNERS UPDATE – Part 2
	• Icddr,b <i>–Firdausi Qadri</i>
	Update on the GTFCC Investment Case, <i>Stefano Malvolti, MMGH</i>
I	<ul> <li>IVI's project on estimating the impact of the Ending Cholera Roadmap, Vittal Mogasale</li> </ul>

	BMGF support to the GTFCC, <i>Tina Lorenson</i>
15.15 -15.30	Coffee Break
15.30-16.30	GTFCC RESEARCH AGENDA AND TECHNICAL GUIDANCE
	Update on the GTFCC Research priorities – Kashmira Data, CDC
	DFID/Wellcome support to the GTFCC Research agenda – <i>Genevieve, Hugh, Wellcome Trust</i>
	Update on the Yellow Book and other GTFCC technical notes – Chesco Nogareda, GTFCC Secretariat
	Group discussion on additional guidance notes on OCV to be developped
16.30-17.00	OCV WG AND NEXT STEPS
	Summary of main points agreed during the meeting and agreement on agenda of work – $David Olson$ , $GTFCC$ Secretariat
	Validation of research priorities – Kashmira Date, CDC
	Final words- Kashmira Date, CDC
	END OF MEETING